Related Experiment Video
Updated: Feb 26, 2026
High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
Published on: December 20, 2024
P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site
Jonathan D Marotti1,2, Kristen E Muller1, Laura J Tafe1,2
1Department of Pathology & Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
Background:
Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 (P-Rex1) has been implicated in cancer growth, metastasis, and response to phosphatidylinositol 3-kinase (PI3K) inhibitor therapy. The aim of this study was to determine whether P-Rex1 expression differs between primary and metastatic human breast tumors and between breast cancer subtypes.
Design:
P-Rex1 expression was measured in 133 specimens by immunohistochemistry: 40 and 42 primary breast tumors from patients who did versus did not develop metastasis, respectively, and 51 breast-derived tumors from metastatic sites (36 of which had matching primary tumors available for analysis).
Results:
Primary breast tumors showed significant differences in P-Rex1 expression based on receptor subtype. ER+ and HER2+ primary tumors showed higher P-Rex1 expression than primary triple-negative tumors. HER2+ metastases from all sites showed significantly higher P-Rex1 expression compared to other metastatic receptor subtypes. Solid organ (i.e., brain, lung, and liver) metastases showed higher P-Rex1 expression compared to bone metastases.
Conclusions:
P-Rex1 expression is increased in ER+ and HER2+ breast cancers compared to triple-negative tumors. P-Rex1 may be differentially expressed in metastatic tumors based on site and receptor status. The role of P-Rex1 in the development of breast cancer metastases and as a predictive biomarker of therapeutic response warrants further investigation.
Insights
Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 (P-Rex1) expression varies in breast cancer. Higher P-Rex1 is seen in ER+ and HER2+ tumors, and in solid organ metastases, suggesting a role in cancer progression.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 (P-Rex1) is linked to cancer growth, metastasis, and PI3K inhibitor response.
- Understanding P-Rex1 expression in different breast cancer stages and subtypes is crucial for targeted therapies.
Purpose of the Study:
- To investigate differences in P-Rex1 expression between primary and metastatic human breast tumors.
- To compare P-Rex1 expression across distinct breast cancer subtypes (ER+, HER2+, triple-negative).
Main Methods:
- Immunohistochemistry was used to quantify P-Rex1 expression in 133 breast tumor specimens.
- Specimens included primary tumors (with and without metastasis) and metastatic tumors from various sites.
Main Results:
- Primary ER+ and HER2+ breast tumors exhibited higher P-Rex1 expression than triple-negative tumors.
- Metastatic HER2+ tumors showed significantly elevated P-Rex1 compared to other subtypes.
- Solid organ metastases (brain, lung, liver) had higher P-Rex1 levels than bone metastases.
Conclusions:
- P-Rex1 expression is elevated in ER+ and HER2+ breast cancers relative to triple-negative tumors.
- Differential P-Rex1 expression in metastases suggests a role in site-specific spread and receptor status.
- Further research is needed to explore P-Rex1's role in metastasis and its potential as a predictive biomarker for treatment response.
